Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Studied

Phase 3 randomized trial comparing two semaglutide doses with placebo, alongside lifestyle intervention, for weight management.

Who / model

1210 adults with overweight or obesity and type 2 diabetes, treated for 68 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

In the main higher-dose comparison, average weight fell 9·6% versus 3·4% with placebo, and 68·8% versus 28·5% lost at least 5%, the two primary outcomes. Digestive adverse events occurred in 63·5% with the higher dose, 57·5% with the lower dose and 34·3% with placebo, mostly mild or moderate.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary